Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of non-psychoactive cannabinoid (“CBD”) and synthetic CBD medicines that address the unmet needs of large patient populations, today announced it has appointed Jerome B. Zeldis, M.D., Ph.D., to its Board of Directors.
Dr. Zeldis serves as the Chief Medical Officer of Celgene Corporation (Nasdaq: CELG). Since 1997, he has been instrumental in the company’s growth to become one of the world’s largest global pharmaceutical firms.
“Dr. Zeldis is a highly accomplished physician and pharmaceutical executive with an impressive track record of bringing important new drugs to market globally,” said Kalytera Co-founder and Board member, David Stefansky. “It’s an exciting time to be at the leading edge of pharmaceutical research, and we are delighted that a pharmaceutical development expert like Jerry has joined our Board.”
Commenting on his appointment to the Kalytera Board, Dr. Zeldis said, “I am intrigued with the potential of the preliminary work on CBD compounds that Kalytera and its research partners have achieved. I am pleased to contribute to the Company’s mission of advancing CBD research to pioneer new pharmaceutical therapies for diseases affecting hundreds of millions of people worldwide.”
About Dr. Jerome B. Zeldis
Dr. Zeldis serves as the Chief Medical Officer of Celgene Corporation where, since 1997, he has been part of the company’s growth to one of the world’s largest global bio-pharmaceutical firms. Dr. Zeldis also serves as the Chief Executive Officer of Celgene Global Health, an organization whose mission is to develop and distribute therapeutics for diseases of the developing world.
Prior to joining Celgene, Dr. Zeldis was Associate Director of Clinical Research at Sandoz Research Institute and Director of Medical Development at Janssen Pharmaceutical Research Institute.
Dr. Zeldis received his training in Internal Medicine at the UCLA Center for the Health Sciences and was a clinical and research fellow in gastroenterology at Massachusetts General Hospital and Harvard Medical School. Additionally, he was an Assistant Professor of Medicine at the Harvard Medical School, an Associate Professor of Medicine at the University of California, a Clinical Associate Professor of Medicine at Cornell Medical School, and a Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick, NJ. Dr. Zeldis has published 112 peer reviewed articles and 43 U.S. patents.
Kalytera Therapeutics, Inc. is a pharmaceutical company that is developing a portfolio of nonpsychoactive cannabinoid and cannabinoid-modulating medicines that address the unmet needs of large patient populations. The Company seeks to commercialize its proprietary, synthetic cannabinoid therapies across a range of disease states, with an initial focus on bone healing and osteoporosis. For more information, visit: https://kalytera.co/.
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management’s estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of Kalytera. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to Kalytera cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, Kalytera will not obtain appropriate or necessary governmental approvals to market these or other potential products, Kalytera may not be able to obtain anticipated funding for its development projects or other needed funding, and Kalytera may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and Kalytera does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.